EBE releases white paper on personalized medicine

Representative body European Biopharmaceutical Enterprises (EBE) has launched a white paper on personalized medicine to set out concepts around personalized medicine, as well as key challenges.

Personalized medicine targets treatments to the patients who are most likely to benefit from them, rather than the traditional “one size fits all” approach to treating a condition. EBE has called for greater investment in e-health and big data infrastructure, establishing data privacy and protection laws and appropriate European regulation to ensure access to methods for correct diagnosis.

Barbara Freischem, executive director of the EBE, said: “We want to pave the way for more patients having access to medicines that are right for them,” while Tom Lillie, chairman of the EBE personalized medicine working group, added: “To achieve this, we need more flexibility in the way we invent, develop, approve, prescribe, reimburse and use medicines. This demands an unprecedented level of collaboration of everyone involved."